Press + news
Telesis Bio Announces Launch of Initial Public Offering
SAN DIEGO, Calif., June 14, 2021 (GLOBE NEWSWIRE) — Telesis Bio, Inc. (“Telesis Bio”), creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today announced the launch of its public offering of 6.7…
Telesis Bio Releases Long Gene Fragment Cloning On The BioXp™ System
Automated synthesis of gene fragments using the BioXp™ system enables overnight production of error-corrected, de novo synthetic genes of up to 7,200 base pairs in length
San Diego, CA, May 04, 2021 – Telesis Bio, Inc., creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, announced the addition of longer fragment cloning to the BioXp™ system. Scientists are now…
Telesis Bio Expands End-to-End Automated Synthetic Biology Workstation Enabling High Throughput Synthesis from DNA Sequence to Biologically Active mRNA
Now offering biologically active mRNA synthesis in a single overnight run on the BioXp™ system
SAN DIEGO — April 27, 2021 — Telesis Bio, Inc., creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today announced the release of a mRNA workflow for the BioXp™ workstation allowing scientists…
Telesis Bio Releases World’s First Synthetic Genomes for Emerging SARS-CoV-2 Variants
New synthetic genomes of the UK and South Africa variants will accelerate discovery and development for vaccines and therapeutics
SAN DIEGO — March 5, 2021 — Telesis Bio, Inc., today announced the release of the world’s first full-length synthetic genomes for two emerging variants of the SARS-CoV-2 virus. The new genomes include the B.1.1.7 variant that initially emerged in…
Telesis Bio Releases New Synthetic Genomes for the Fight Against COVID-19
Seven new SARS-CoV-2 genomes will accelerate vaccine and therapy development
SAN DIEGO – (GLOBE NEWSWIRE) – Telesis Bio, Inc. today announced the release of seven new synthetic SARS-CoV-2 genomes for use in the development of vaccines, therapeutics, and diagnostics to help in the COVID-19 pandemic response. With our BioXp™ 3250 system,…
Telesis Bio Demonstrates Momentum Toward Mission of Building World’s First Vaccine Printer and Global Vaccine Network
The Digital-to-Biological Converter will enable printing life-saving vaccines on a global scale using synthetic DNA to stop future pandemics
SAN DIEGO – (GLOBE NEWSWIRE) – Telesis Bio, Inc., creators of the world’s first fully automated system for high-throughput writing of DNA, today announced critical advancements in its development of the Digital-to-Biological Converter™ (DBC) platform. The platform will enable the direct…
Telesis Bio Launches New Automated Synthetic Biology Workstation for Commercial Use
The new BioXp™ 3250 system – a fully automated, benchtop platform for synthetic biology workflows – dramatically accelerates the development of critical new vaccines and biologics
SAN DIEGO – (GLOBE NEWSWIRE) – Today, Telesis Bio, Inc., creators of the world’s first fully automated system for high-throughput DNA printing, announced the introduction of their next-generation platform, the BioXp™ 3250 system. This system reduces the timelines for identifying vaccine and…
Telesis Bio Releases New Synthetic SARS-CoV-2 Genome for COVID-19 Vaccine and Therapeutic Research
New version represents dominant variant of the virus responsible for COVID-19 to enable relevant research and development of clinical treatments
SAN DIEGO – (GLOBE NEWSWIRE) – Telesis Bio, Inc., today announced the release of a new synthetic SARS-CoV-2 genome developed to accelerate research on the latest and the most dominant strain of the SARS-CoV-2 virus responsible for the COVID-19 pandemic. The…
Telesis Bio announces 8 new products to support the scientific community’s battle against COVID-19
Pioneering synthetic DNA company releases a wide range of antigen panels, synthetic DNA parts, and vaccine scaffolds to expedite vaccine development, drug discovery, and diagnostics
SAN DIEGO – (GLOBE NEWSWIRE) – Telesis Bio, Inc., creators of the world’s first fully automated system for high-throughput writing of DNA, the BioXp™ 3200 system, today announced a newly developed and released suite of products and services designed to accelerate…
SGI-DNA Equipping Researchers With Critical Tools to Combat Coronavirus Disease (COVID-2019)
Synthetic biology company taking major steps in worldwide effort to put a stop to the SARS-CoV-2 (formerly known as 2019-nCoV) outbreak, including co-funding purchases of BioXp™ 3200 System. SGI-DNA is enabling researchers to quickly print DNA required to discover vaccines and therapeutics.
SAN DIEGO – (BUSINESS WIRE) – SGI-DNA, creators of the BioXp™ 3200 System and Gibson Assembly® Reagents, announces a focused effort to empower organizations to accelerate research focused on creating vaccines for SARS-CoV-2. SGI-DNA is building resources to support partners in the…
SGI-DNA Launches Vmax™ X2, the Most Innovative Product in the Competent Cells Market Since the Discovery of E. coli
Pioneering synthetic biology company, SGI-DNA, releases a new protein expression system, accelerating research into vaccines and personalized medicines by delivering up to 4x more soluble protein than traditional E. coli methods in half the time
SAN DIEGO – (BUSINESS WIRE) – SGI-DNA, creators of the BioXp™ 3200 System and Gibson Assembly® Reagents, has launched Vmax™ X2 Competent Cells, designed to generate two to four times more soluble protein in half of the time of current methods…
SGI-DNA Launches Gibson Assembly® RapidAMP™ Technology for its BioXp™ Gene Builder
The technology allows for mammalian transfection-ready DNA constructs to be synthesized, assembled into custom vectors, and amplified in a single day on the BioXp™ Gene Builder, eliminating the need to clone and copy DNA in E. coli
SAN DIEGO – (BUSINESS WIRE) – SGI-DNA announces the launch of Gibson Assembly® RapidAMP™ technology—a novel approach that allows for cell-free synthesis and amplification of transfection-ready quantities of synthetic DNA. The application has been integrated onto the BioXp™ 3200 Gene Builder and…
Gibson Assembly® Advances Field of DNA Digital Data Storage
Gibson Assembly strategy successfully employed to significantly increase the throughput of DNA data storage and retrieval
SAN DIEGO – (BUSINESS WIRE) – Researchers from the University of Washington and Microsoft announced a DNA assembly strategy for nanopore data storage, reporting that the Gibson Assembly® Method was exceptionally effective in retrieving information stored in DNA. The strategy successfully…